膀胱过度活动症：确保治疗依从性的策略
Overactive bladder: strategies to ensure treatment compliance and adherence.
作者信息
Dhaliwal Prabhpreet, Wagg Adrian
机构信息
Department of Medicine, University of Alberta, Edmonton, Canada.
出版信息
Clin Interv Aging. 2016 Jun 3;11:755-60. doi: 10.2147/CIA.S69636. eCollection 2016.
Abstract
Overactive bladder is a common, debilitating condition for many patients who may benefit from pharmacological management of their condition. However, adherence to medication in this condition is markedly worse than other chronic medical conditions. This review explores what is known about persistence and the factors which influence medication adherence for overactive bladder, those factors that might be modifiable to improve adherence, and the measures the health care provider can take to optimize adherence to therapy and thereby improve treatment outcomes.
摘要
膀胱过度活动症是一种常见且使许多患者衰弱的病症，这些患者可能从该病症的药物治疗中获益。然而，这种病症下的药物依从性明显低于其他慢性疾病。本综述探讨了关于膀胱过度活动症持续用药情况的已知信息、影响药物依从性的因素、那些可能可改变以提高依从性的因素，以及医疗保健提供者为优化治疗依从性从而改善治疗效果可采取的措施。
相似文献
1
Overactive bladder: strategies to ensure treatment compliance and adherence.
Clin Interv Aging. 2016 Jun 3;11:755-60. doi: 10.2147/CIA.S69636. eCollection 2016.
2
Persistence and compliance with medication management in the treatment of overactive bladder.
Investig Clin Urol. 2016 Mar;57(2):84-93. doi: 10.4111/icu.2016.57.2.84. Epub 2016 Mar 11.
3
Persistence with medication and overactive bladder: an ongoing challenge.
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):475-81. doi: 10.1080/14737167.2016.1203258. Epub 2016 Jul 4.
4
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
J Urol. 2014 Apr;191(4):1003-8. doi: 10.1016/j.juro.2013.10.046. Epub 2013 Oct 16.
5
Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.
BMC Urol. 2017 Apr 13;17(1):30. doi: 10.1186/s12894-017-0216-4.
6
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
BMJ Open. 2018 Nov 21;8(11):e021889. doi: 10.1136/bmjopen-2018-021889.
7
A review of adherence to drug therapy in patients with overactive bladder.
BJU Int. 2008 Sep;102(7):774-9. doi: 10.1111/j.1464-410X.2008.07769.x. Epub 2008 Jul 4.
8
Overactive bladder medication adherence when medication is free to patients.
J Urol. 2010 Mar;183(3):1077-81. doi: 10.1016/j.juro.2009.11.026. Epub 2010 Jan 21.
9
Long-term persistence with mirabegron in a real-world clinical setting.
Int J Urol. 2018 May;25(5):501-506. doi: 10.1111/iju.13558. Epub 2018 Apr 12.
10
Adherence to fesoterodine in women with overactive bladder in routine clinical practice.
Actas Urol Esp. 2015 May;39(4):222-8. doi: 10.1016/j.acuro.2014.05.013. Epub 2014 Oct 25.
引用本文的文献
1
The Efficacy of an Active Medicinal Alkaloid, Berbamine, in Reducing Overactive Bladder Symptoms in a Retinyl Acetate-Induced Model.
Biomolecules. 2025 Jan 29;15(2):190. doi: 10.3390/biom15020190.
2
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis.
Rev Bras Ginecol Obstet. 2023 Jun;45(6):337-346. doi: 10.1055/s-0043-1770093. Epub 2023 Jul 21.
3
Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States.
J Int Med Res. 2022 May;50(5):3000605221098176. doi: 10.1177/03000605221098176.
4
The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US.
Pharmacoecon Open. 2021 Dec;5(4):727-736. doi: 10.1007/s41669-021-00281-8. Epub 2021 Jul 13.
5
Urinary Microbiome: Yin and Yang of the Urinary Tract.
Front Cell Infect Microbiol. 2021 May 18;11:617002. doi: 10.3389/fcimb.2021.617002. eCollection 2021.
6
Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management.
Int J Clin Pract. 2020 Nov;74(11):e13604. doi: 10.1111/ijcp.13604. Epub 2020 Jul 27.
7
Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study.
Int Braz J Urol. 2020 Mar-Apr;46(2):185-193. doi: 10.1590/S1677-5538.IBJU.2019.0094.
8
Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women.
Am J Obstet Gynecol. 2020 Feb;222(2):159.e1-159.e16. doi: 10.1016/j.ajog.2019.08.025. Epub 2019 Aug 23.
9
Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity.
Urol Ann. 2017 Jul-Sep;9(3):249-252. doi: 10.4103/UA.UA_172_16.
本文引用的文献
1
Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data.
J Health Econ Outcomes Res. 2016 Oct 28;3(1):43-55. doi: 10.36469/9841. eCollection 2015.
2
Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):343-50. doi: 10.5489/cuaj.3098.
3
Factors affecting medication adherence in Lebanese patients with chronic diseases.
Pharm Pract (Granada). 2015 Apr-Jun;13(3):590. doi: 10.18549/PharmPract.2015.03.590. Epub 2015 Jun 15.
4
Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.
Int J Clin Pract. 2015 Nov;69(11):1309-15. doi: 10.1111/ijcp.12705. Epub 2015 Jul 28.
5
Packaging interventions to increase medication adherence: systematic review and meta-analysis.
Curr Med Res Opin. 2015 Jan;31(1):145-60. doi: 10.1185/03007995.2014.978939. Epub 2014 Nov 4.
6
Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.
Postgrad Med. 2014 May;126(3):246-56. doi: 10.3810/pgm.2014.05.2773.
7
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11.
8
Patient characteristics associated with medication adherence.
Clin Med Res. 2013 Jun;11(2):54-65. doi: 10.3121/cmr.2013.1113. Epub 2013 Apr 11.
9
[European Association of Urology guidelines on assessment and nonsurgical management of urinary incontinence].
Actas Urol Esp. 2013 Apr;37(4):199-213. doi: 10.1016/j.acuro.2012.12.001. Epub 2013 Feb 27.
10
Dosing frequency and medication adherence in chronic disease.
J Manag Care Pharm. 2012 Sep;18(7):527-39. doi: 10.18553/jmcp.2012.18.7.527.
Zotero 插件